Medicine and Dentistry
Bone Turnover
97%
Bone Density
75%
Placebo
46%
Osteolysis
36%
Osteoporosis
30%
Tibia
28%
Osteocalcin
26%
Amino Terminal Sequence
26%
Randomized Controlled Trial
25%
Procollagen
25%
Bone Mass
25%
Bone Remodeling
24%
Bone Strength
24%
Ossification
23%
Maturity Onset Diabetes of the Young
22%
Patient with Type 2 Diabetes
20%
Receptor
18%
Roux-en-Y Gastric Bypass
18%
Spondylarthritis
18%
Glucagon-Like Peptide-1 Agonist
17%
Biochemical Marker
16%
Quantitative Computed Tomography
16%
Magnetic Resonance Imaging
16%
Exenatide
15%
Biological Marker
15%
Cardiovascular System
14%
Sacroiliac Joint
14%
Osteoblast
13%
Patient with Epilepsy
13%
Whole Body Vibration
13%
Hip Fracture
13%
Adolescence
13%
Dual-Energy X-Ray Absorptiometry
13%
Bone Mineral
13%
Hip
13%
Diabetes
12%
Body Weight
12%
Purinergic P2X7 Receptor
12%
Insulin Dependent Diabetes Mellitus
12%
Glycon
12%
Body Mass Index
12%
Collagen Type 1
11%
Prospective Study
11%
Metabolic Bone Disease
11%
Cross Sectional Study
10%
X-Ray Microtomography
10%
Spinal Cord Injury
10%
Exercise
9%
Isotopes of Calcium
9%
Gastric Bypass Surgery
9%
Biochemistry, Genetics and Molecular Biology
Bone Turnover
100%
Bone Density
54%
Osteolysis
41%
Bone Remodeling
39%
N-Terminus
36%
Adolescence
32%
Osteocalcin
27%
Ossification
23%
Whole Body Vibration
23%
Osteoblast
21%
Bone Mass
19%
Parathyroid Hormone
17%
Blood Plasma
17%
Type I Collagen
17%
Alkaline Phosphatase
16%
Bone Strength
16%
Osteoclast
15%
Randomized Controlled Trial
14%
Gastric Inhibitory Polypeptide
13%
Stem Cell
13%
Reference Value
12%
Mineralization
10%
C-Terminus
10%
Allele
9%
Drug Megadose
9%
Mouse Model
9%
X-Linked Hypophosphatemia
9%
Porosity
8%
Postmenopause
8%
Single-Nucleotide Polymorphism
7%
Receptor Gene
6%
Premenopause
6%
Purinergic Receptor
6%
Sclerostin
6%
Cortisol
6%
Melatonin
6%
Prevalence
5%
Wild Type
5%
Signal Transduction
5%
Glucose Blood Level
5%
Muscle Strength
5%
Exercise
5%
Glucagon-Like Peptide 1 Receptor
5%
Receptor Agonists
5%
Knockout Mouse
5%
Osteocyte
5%
Sleep Quality
5%
C-Terminal Telopeptide
5%
Glucagon-Like Peptide-1
5%
Physical Performance
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
41%
Purinergic P2X7 Receptor
19%
Metabolic Bone Disease
17%
Glucagon Like Peptide 1 Receptor Agonist
16%
Procollagen
16%
Randomized Controlled Trial
15%
Exendin 4
15%
Biochemical Marker
14%
Antipsychotic
13%
Biological Marker
12%
Clopidogrel
12%
Cerebrovascular Accident
12%
Inflammation
11%
Postmenopause Osteoporosis
11%
Non Insulin Dependent Diabetes Mellitus
11%
Hyponatremia
10%
Receptor
9%
Bisphosphonic Acid Derivative
9%
Mouse Model
9%
Hip Fracture
9%
Cluster Headache
9%
Parathyroid hormone[1-34]
9%
Receptor Antagonist
9%
Purinergic P2X Receptor
9%
Gastric Inhibitory Polypeptide
9%
Troponin
9%
Vitamin D
8%
Adverse Event
7%
Brain Ischemia
7%
Heart Infarction
7%
Clinical Trial
7%
Metformin
7%
Diabetes Mellitus
7%
Calcitonin Gene Related Peptide
7%
Clinical Study
6%
Transient Ischemic Attack
6%
Anticonvulsive Agent
6%
Osteocalcin
6%
Vasculotropin
5%
Hyperlipidemia
5%
Purinergic P2Y12 Receptor
5%
Combination Therapy
5%
Pathophysiology
5%
Parathyroid Hormone
5%
